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372Objective: Our objectives were 3-fold: to define the correlation between automated volumetric and
2-dimensional measurements of pulmonary nodule growth and prospectively; to determine whether volu-
metric growth analysis represents a useful addition to 2-dimensional measurements; and to evaluate growth
rates over time of biopsy-proven lung cancers using automated volumetric software.
Methods: Nodule growth on consecutive 2-dimensional computed tomographic scans was measured, and a de-
cision regarding nodule biopsy was made. Automated volumetric software was then used to determine nodule
growth, growth rates obtained from the 2 techniques were correlated, and the decision to perform a biopsy was
reassessed. Biopsy-proven lung cancer growth rates were then documented over time.
Results:Growth rates measured using volumetric software were highly correlated with 2-dimensional measure-
ments (r ¼ 0.69; P<.00001). This correlation was affected by nodule type (irregular [r ¼ .63] versus smooth
[r ¼ 0.84]; P ¼ .02) as well as the interval between scans (<100 days [r ¼ .5] versus>100 days [r ¼ 0.76];
P ¼ .02). The addition of volumetric growth analysis changed the decision to perform a biopsy after only a mi-
nority (6.2%) of scan comparisons; however, lung cancer was diagnosed in 43% of these cases. Growth curves
for individual cancers were highly variable, with 45% of tumors showing at least 1 period of shrinkage.
Conclusions: Automated volumetric software influences biopsy decisions in only a minority of cases in a ded-
icated pulmonary nodule clinic, but seems to be useful in detecting lung cancer in this minority. Radiographi-
cally determined nodule growth rates, in general, need to be questioned as the sole determinate of the need to
perform a biopsy. (J Thorac Cardiovasc Surg 2011;142:372-7)Earn CME credits at
http://cme.ctsnetjournals.org
With the increasing use of computed tomography (CT) for
imaging of the chest and abdomen, the discovery of inciden-
tal indeterminate pulmonary nodules (IPN) is common-
place.1 Despite their high frequency, the rate of
malignancy in CT-detected IPN is low, ranging from
0.4% to 2.7%.1 Nodules with documented growth are gen-
erally thought to be more likely to represent malignancy
than are those that either remain stable or decrease in size.2
The purpose of this study is 3-fold. First, we sought to de-
termine the growth of IPN in a dedicated pulmonary nodule
clinic (PNC) in a prospective fashion using 2-dimensional
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The Journal of Thoracic and Cardiovascular Surgwith automated volumetric CT assessments of growth. Sec-
ond, we sought to prospectively determine how often the ad-
dition of automated volumetric assessments of nodule
growth changed the decision to perform a biopsy in this pa-
tient population. Third, the volumetrically determined
growth characteristics of all biopsy proven lung cancers in
this study were detailed to determine whether measuring
growth rates is indeed a valuable tool in the assessment of
lung nodules.METHODS
Dedicated PNC
The institutional review board waived the need for informed consent for
this study. A dedicated PNCwas initiated at a single institution in 2007, the
sole purpose being to differentiate benign from malignant lung nodules.
Any patient with 1 to 5 undiagnosed pulmonary nodules up to 3 cm in
size without evidence of adenopathy or local invasion into neighboring
structures was referred into the PNC. The present study, however, encom-
passes only PNC patients with either solid or part-solid nodules greater
than 5 mm in diameter as measured on standard, 2D CT who had more
than 1 scan for comparison. In addition, patients with known lung cancer
in another synchronous nodule were excluded, as were those whose nod-
ules could not be segmented reliably either by the automated volumetric
software or manually by the radiologist.
Decisions regarding biopsy of nodules were made by a single physician
(R.J.K.) and were dependent on clinical information obtained from each
patient’s history, positron emission tomography (PET; performed when
deemed appropriate), nodule appearance (size and shape) on 2D CT
scan, and evidence of nodule growth when comparing 2 consecutive CT
scans.ery c August 2011
Abbreviations and Acronyms
CT ¼ computed tomography
2D ¼ 2-dimensional
IPN ¼ indeterminate pulmonary nodules
PET ¼ positron emission tomography
PNC ¼ pulmonary nodule clinic
Korst et al General Thoracic Surgery
G
T
SCT
All CT studies were performed on 1 of 3 CT scanners including an 8- or
64-detector GE CT (Lightspeed Ultra or VCT; GE Healthcare, Milwaukee
Wis) and a 4-detector CT (Siemens Sensation 4; Siemens Medical Solu-
tions, Forchheim Germany). Scanning of the entire thorax was performed
in a craniocaudal direction in deep inspiration in the supine position. Scan-
ning datawere obtained in the spiralmodewith collimation of .625mmwith
64 detectors (pitch¼ 1), 1.25mmwith 8 detectors (pitch¼ 1.4), and 1.0mm
with 4 detectors (pitch¼ 1.5), respectively. No contrastmaterialwas admin-
istered. For all machines and patients, kilovolt peak was kept constant at
120. The tube current–time product settings were adjusted accordingly to
provide the lowest dose settings applied. Data were reconstructed at 1.0-
to 1.25-mm section thickness with a 1.0- to 1.25-mm reconstruction incre-
ment. Volumetric analysis of pulmonary nodules was performed on a dedi-
cated workstation (GE Advantage Windows v4.3) using commercially
available software (Advanced Lung Analysis; GE Healthcare).
Pulmonary Nodule Growth Measurements
Nodule growth was assessed in 2 ways: 2D and volumetric. For 2D
growth assessment, a single physician (R.J.K.) compared individual CT
lungwindow images of nodules side by side.Nodule sizewasmeasured after
fitting the image to 100% on the institutional picture archive and communi-
cation system using electronic calipers in 2 perpendicular dimensions on the
CT imagewhere it appeared the largest. Carewas taken to measure the nod-
ule on consecutive scans as close as possible to the same ‘‘cut.’’ The 2 dimen-
sions were then multiplied together to yield a nodule size in cm2. Nodule
growthwas then calculated by the following formula: Size (second scan)mi-
nus size (first scan) divided by size (first scan), multiplied by 100. For part-
solid lesions, only the solid component was used in the growth calculation.
Volumetric growth assessments were made for all scan comparisons, ac-
cording to the manufacturer’s instructions by institutional radiologists. Au-
tomated nodule segmentation (the ability to extract the nodule from the
background of pulmonary parenchyma and vasculature) was used in all
cases unless it was deemed inappropriate by the radiologist (eg, nodule
abuts the pleura or large blood vessel), in which case the nodule was seg-
mented manually. The technique is semiautomated whereby the user drops
a point in the middle of the nodule from 2 separate CT examinations at dif-
ferent time intervals. In the majority of cases the extraction of the nodule
from the background pulmonary parenchyma and vasculature is successful
by the software. If the extraction includes structures other than the nodule
of interest (usually blood vessels or pleura), the user narrows the region of
interest to exclude the unwanted structures. Once segmented, the auto-
mated software calculated both growth rate as well as doubling time (dou-
bling time only calculated for lesions growing in size). For part-solid
lesions, only the solid component was used in the growth calculation. Au-
tomated volumetric analysis added approximately 3 to 5 minutes of time on
to the radiologist’s reading of the scan.
To graphically display the growth characteristics of all lung cancers
evaluated with volumetric imaging over time (including those that shrunk
in size), we computed a growth index according to the following formula:
Growth rate (percent) divided by scan interval (days). Therefore, a doubling
of the growth index between 2 cancers suggests that 1 tumor is growing
twice as fast as the other.The Journal of Thoracic and CaData Collection
All data were collected prospectively and included patient demograph-
ics, radiographic data (nodule type, size, growth rate and doubling time,
and time interval between scans), PET data, as well as biopsy and treatment
data. Nodule type was defined as solid/smooth, solid/irregular (spiculated
and/or lobulated), or part-solid. PET was not performed routinely for all
nodules. When performed, PET examinations were interpreted by institu-
tional radiologists as positive or negative when comparing the nodule to
the uptake in the mediastinal blood pool. If positive, the maximum stan-
dardized uptake value was reported. Biopsy data included the type, result,
and complications of biopsy, whereas treatment data related only to those
patients with a diagnosis of lung cancer. All data were entered into a PNC-
specific database.
Patients undergoing follow-up CT imaging (after an initial scan that re-
vealed a nodule) were seen by a single physician on the same day as the
follow-up scan (‘‘prospective’’ cases). During this office visit, a decision
regarding biopsy was made on the basis of clinical data, PET data (when
performed), nodule appearance on CT, and 2D growth assessment. Volu-
metric analysis was then performed by a radiologist within the next 5
days, after which the decision regarding biopsy was revisited, based on
the results of volumetric analysis.
A minority of patients came initially to the PNC with more than 1 scan
and volumetric growth analysis already performed (‘‘nonprospective’’
cases). In these cases, the effect of volumetric analysis on the decision to
perform a biopsy could not be assessed prospectively inasmuch as the vol-
umetric data were available at the time of the initial office visit.
Statistical Analysis
Two-dimensional growth rates were correlated with volumetric growth
rates yielding a Pearson correlation coefficient (r) using a commercially
available software package (Microsoft Excel, Redmond, Wash), and
a 95% confidence interval (CI) was calculated. Subgroup analysis was con-
ducted, and values of r were compared using Fisher’s z test3 (2-tailed test).RESULTS
CT Scan Comparisons
In the context of the PNC, a total of 129 assessments of
2D and automated volumetric growth rates were made
over a 27-month period for either solid or part-solid nodules
(both ‘‘prospective’’ and ‘‘nonprospective’’ comparisons).
These assessments were made in the process of evaluating
87 nodules in 69 patients by comparing 2 sequential CT
scans. This study cohort comprised 44 (64%) women
with a mean age of 62 years (range, 42-90). Table 1 depicts
the radiographic characteristics of these 87 nodules. The
mean time interval between scans was 5.7 months (range,
0.5-32 months). For 33 comparisons, the second scan was
performed within 3 months of the first (26%).Correlation Between 2D and Automated Volumetric
Assessments of Growth
For all scan comparisons (both ‘‘prospective’’ and ‘‘non-
prospective’’), growth rates for all nodules were determined
by both 2D and volumetric techniques, as described in
‘‘Methods.’’ The 2D growth rates were then correlated
with those obtained using automated volumetric software
for all 129 comparisons and found to be significantly corre-
lated (Figure 1). To examine the effect of nodule size on thisrdiovascular Surgery c Volume 142, Number 2 373
TABLE 1. CT characteristics of 87 indeterminate pulmonary nodules
in 69 patients
CT characteristic No. of cases (%)
Subcentimeter 55 (63%)
Nodule type
Solid/irregular 55 (63%)
Solid/smooth bordered 25 (29%)
Part solid 7 (8%)
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Scorrelation, we divided nodules into subcentimeter lesions
and those 1 cm or larger in greatest diameter at initial presen-
tation. Interestingly, the correlation between 2D and volu-
metric assessments of growth seemed to be slightly better
for subcentimeter nodules than for nodules greater than or
equal to 1 cm, although this difference was not statistically
significant (r ¼ 0.73 vs r ¼ 0.63, respectively; P ¼ .32). A
statistically significant increase in the correlation between
the 2 growth measurement techniques was detected, how-
ever, for solid/smooth lesions compared with solid/irregular
lesions (r¼ 0.84 vs r¼ 0.63; P¼ .02). Finally, a statistically
significant difference in correlation between 2D and volu-
metric measurements of growth was detected depending on
the time interval between the scans being compared. When
the scan interval was less than 100 days, the correlation be-
tween 2D and volumetric assessments of growth was signif-
icantly worse than that seen when the scan interval was 100
days or greater (r¼ 0.50 vs r¼ 0.76, respectively; P¼ .02).
The Effect of Automated Volumetric Growth
Assessments on the Decision to Perform a Biopsy
For a total of 113 (88%) of 129 scan comparisons, deci-
sions regarding biopsy were initially made incorporating0
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FIGURE 1. Correlation between nodule growth rates determined using
automated volumetric software and conventional, 2-dimensional measure-
ments as described in ‘‘Methods.’’ Each data point represents a comparison
between 2 consecutive scans (n ¼ 129; r ¼ 0.69; 95% CI: 0.59-0.77;
P<.00001).
374 The Journal of Thoracic and Cardiovascular Surg2D imaging because the volumetric analysis of growth
was not reported until approximately 5 days after the pa-
tient’s office visit (‘‘prospective’’ cases; see ‘‘Methods’’).
For these prospective cases, the decision regarding the per-
formance of a biopsy was then reevaluated after review of
the volumetric data.
Biopsy was recommended after 37 of 113 (33%) pro-
spective scan comparisons. These 37 comparisons were per-
formed for 35 nodules in 32 patients (3 patients had 2
nodules needing biopsy, and 2 patients refused the initial
recommendation for biopsy and did not undergo biopsy un-
til another scan was performed). For 30 comparisons (81%
of biopsy decisions), the decision to perform a biopsy was
made after analysis of the clinical and radiographic data be-
fore the performance of volumetric growth analysis. In no
instance did the volumetric analysis reverse the decision
to perform a biopsy that had been previously made using
the 2D data.
In 7 patients (6.2% of total scan comparisons; 19% of bi-
opsy decisions), observation was recommended after anal-
ysis of 2D radiographic data, but this decision was
reversed after review of the volumetric data, with biopsies
being ordered in all 7 patients. Details of these cases are de-
picted in Table 2. Non–small cell lung cancer was diag-
nosed in 3 (43%) of these 7 patients.
Lung Cancer Characteristics
Lung cancer was diagnosed by biopsy in 20 of 69 patients
(29% of patients, 23% of nodules). A total of 36 scan com-
parisonswere performed for these 20 patients (1 comparison
in 10 patients; 2 comparisons in 7 patients; 3 comparisons in
1 patient; 4 comparisons in 1 patient; 5 comparisons in 1
patient). Table 3 displays the clinical characteristics of
these 20 patients.
Lung cancer growth over serial scan comparisons as de-
termined using volumetric analysis is displayed graphi-
cally as the growth index in Figure 2. Interestingly, of
the 36 scan comparisons, 10 (28%) suggested that the
lung cancer was shrinking. Only 11 tumors (55%) exclu-
sively enlarged, and 8 tumors had periods of both enlarge-
ment and shrinkage. One tumor actually shrank over
a period of 3 scans (2 comparisons) and never grew before
its removal.
DISCUSSION
The differentiation of malignant from benign pulmo-
nary nodules represents a common dilemma for clinicians
in the modern era of high-resolution CT. Nodule growth,
measured on serial CT examinations, is thought to be a use-
ful tool in identifying IPN that are suggestive of malig-
nancy.2 To this end, automated volumetric software has
been developed that may provide more reproducible mea-
surements of growth than conventional, 2D analysis. Al-
though radiographic studies have been performed thatery c August 2011
TABLE 2. Characteristics of 7 patients in whom biopsy was recommended only after review of volumetric growth analysis
Patient Nodule size* Nodule type 2D growth rate Volumetric growth rate Doubling timey Biopsy result
1 6.9 Solid/irregular 15% 55% 250 No biopsyz
2 19.6 Solid/irregular 37% 28% 261 Inflammatory
3 13.8 Solid/irregular 6% 30% 358 Lung cancer
4 8.2 Solid/smooth 29% 47% 347 Lung cancer
5 11.9 Part solid 36% 41% 432 Inflammatory
6 7.1 Solid/smooth 10% 37% 637 Lymph node
7 7 Solid/irregular 8% 10% 670 Lung cancer
*Greatest diameter in millimeters on 2-dimensional (2D) computed tomographic scan. yDays; determined by automated volumetric software. zNodule regressed at time of sched-
uled biopsy.
Korst et al General Thoracic Surgerysuggest this may be true,4-7 the impact of volumetric
growth assessment on the management of patients with
IPN is not well described. In addition, few studies exist
that prospectively evaluate the effect of volumetric
imaging on clinical decision making in this patient
population.
In terms of cost, volumetric analysis of pulmonary nod-
ules requires an initial software purchase ranging from ap-
proximately $20,000 to $70,000, depending on the vendor.
Some vendors will include volumetric software with the
purchase of a new CT instrument. The Centers for Medi-
care/Medicaid Services provides reimbursement with
a global component of $108 of which the professional com-
ponent is $43.TABLE 3. Clinical characteristics of 20 biopsy-proven lung cancers
detected in the Pulmonary Nodule Clinic and evaluated by
volumetric growth analysis
Characteristic No. of cases (%)
‘‘Prospective’’ (see ‘‘Methods’’) 16 (80%)
Subcentimeter 7 (35%)
Nodule type
Solid/irregular 12 (60%)
Solid/smooth bordered 5 (25%)
Part solid 3 (15%)
PET result
Positive 8* (40%)
Negative 11 (55%)
Not performed 1 (5%)
Treatment
Lobectomy 12 (60%)
Sublobar resection 6 (30%)
Sublobar resection/brachytherapy implant 1 (5%)
Stereotactic body radiotherapy 1 (5%)
Histology
Adenocarcinoma 13 (65%)
Squamous 2 (10%)
Adenosquamous 2 (10%)
Small cell 1 (5%)
Non–small cell 1 (5%)
Typical carcinoid 1 (5%)
Pathologic stage I 20 (100%)
*Mean maximum standardized uptake value for the 8 positive positron emission
tomographic (PET) scans was 3.9 (range, 2.2-7.1).
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SCorrelation of 2D Assessments of Nodule Growth
With Volumetric Analysis
Agreement between the 2 measurement techniques of
IPN growth is an important parameter to assess, because
if they are highly correlated, the use of volumetric analysis
may add very little to conventional, 2D measurements. In
this regard, the data in the present study, as a whole, suggest
that a significant correlation does indeed exist between the 2
measurement techniques. This high degree of correlation is
most likely due to the fact that nodule sizes were compared
side by side by a single physician, using the same measure-
ment technique on similar ‘‘cuts’’ of the scans. Clearly,
given thewidely recognized interobserver and intraobserver
variation in the literature that accompanies 2D measure-
ment of nodule size,4,5,8,9 as well as variation owing to
differing scan parameters,10 our data underscore the need
for clinicians to minimize these variables in the interpreta-
tion of nodule growth.
To probe the relationship between growth measurement
techniques further, we evaluated the effects of nodule typeScan comparison
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FIGURE 2. Growth rates over time for 20 biopsy-proven lung cancers. A
growth index was calculated for each scan comparison as described in
‘‘Methods,’’ which accounts for the time interval between scans. A dou-
bling of the growth index corresponds to a doubling of the growth rate.
Each data point represents a comparison between 2 consecutive scans.
Data points below the dotted line imply tumor shrinkage.
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Sand size, as well as scan interval, on the correlation between
2D and volumetric growth analysis. The finding that growth
rates measured by the 2 different techniques were signifi-
cantly more highly correlated for solid/smooth nodules
than for solid/irregular nodules makes inherent sense inas-
much as irregular borders are more difficult to reproducibly
measure with electronic calipers. This finding implies that
volumetric growth measurements may be more useful
when evaluating irregular lesions, although reproducibility
may also be sacrificed to some extent even when using vol-
umetric analysis.6,11,12 In contrast, even 2Dmeasurement of
subcentimeter nodules correlated well with volumetric
growth analysis in the present study. This finding may be
due to the fact that scans were uniformly performed with
a 1.25-mm slice thickness, and the minimum nodule
diameter was 5 mm.
Finally, the present data show that the longer the time
interval between scans, the higher the correlation between
2D and volumetric growth measurements. This implies
that volumetric analysis may be more useful when the
scan interval is short. This finding also makes intuitive
sense because changes in nodule size are likely to be
more subtle when scans with a short interval are
compared.
The Effect of Volumetric Growth Analysis on Clinical
Decision Making
In everyday clinical practice, the decision to obtain a bi-
opsy specimen of an IPN may be dependent on several fac-
tors, including historical data (patient age, smoking history,
family history), PET data, as well as CT data (nodule ap-
pearance, location, and growth rate). As an example, in
the present study, biopsy specimens were obtained in 3 of
20 lung cancers even though there was no evidence of either
2D or volumetric growth on serial scans. The decision to ob-
tain biopsy specimens in these cases was based on historical
data, PET data, and the appearance of the lesion on CT im-
ages. As a result, it is important to determine whether the
addition of volumetric analysis to the clinician’s armamen-
tarium actually causes a change in the decision to perform
a biopsy that had been made in the absence of volumetric
analysis.
In the present study, the addition of volumetric analysis to
the ‘‘conventional’’ evaluation of IPN changed the decision
to perform a biopsy in a minority (6.2%) of scan compari-
sons. All of these changes involved the decision to perform
a biopsy in cases in which specimens otherwise would not
have been obtained. At first glance, this information, com-
bined with the highly significant correlation between 2D
and volumetric growth analysis described above, suggests
that volumetric analysis adds very little to conventional
evaluation of IPN. However, the finding that 43% of these
cases (where volumetric analysis triggered the performance
of a biopsy) resulted in the diagnosis of lung cancer sug-376 The Journal of Thoracic and Cardiovascular Surggests that in a minority of cases, volumetric growth analysis
may have clinical value.
The Natural Growth History of Malignant
Pulmonary Nodules
Our lung cancer growth data, as shown in Figure 2, con-
firm similar data reported in other publications, in that
most lung cancers, when observed over time, possess highly
variable growth rates.13,14 Further, some lung cancers will
go through periods in which they actually shrink, only to
be followed by periods of growth. Intuitively, shrinkage
may be more likely to be detected volumetrically when the
scan interval is very short. These findings have the
following clinical implications. First, absence of measured
growth, whether 2D or volumetric, does not preclude
a diagnosis of malignancy. Second, although some lung
cancers seem to be indolent, measured growth rates may
change rapidly, implying a more aggressive clinical course
in a previous indolent tumor. Finally, the concept of tumor
doubling time, specifically the definition of a ‘‘benign’’
doubling time, becomes ambiguous because individual
tumors may change doubling times throughout their
natural history.
Strengths and Limitations of the Present Analysis
Strengths of this study include the prospective data col-
lection, as well as the ability to assess the clinical impact
of volumetric imaging prospectively. In addition, the rela-
tive uniformity in which the CT scans were performed
and interpreted excludes a major source of potential vari-
ability in the results. Although some variation in radiation
dose exists in the present cohort of scans, published litera-
ture suggests that radiation dose most likely does not affect
the ability to reproducibly measure nodule size using auto-
mated volumetric software.15,16
Despite these strengths, several limitations of the present
study exist. First, a weakness inherent in any study involv-
ing the in vivo accuracy of any imaging technology is that
the actual size of a given IPN is not truly known. Only in
investigations using phantom nodules are the true sizes
known, and in these studies, volumetric analysis of nodule
size and growth is extremely reproducible.
A second limitation is that decisions to obtain biopsy
tissue were not based on explicitly defined growth crite-
ria. Clearly, the most rigorous investigation of the impact
of nodule growth on clinical decision making would in-
clude strict growth criteria for biopsy, as described in
the NELSON screening trial.2 In the NELSON trial, the
decision to perform a biopsy after obtaining incidence
scans was based solely on nodule growth, according to
strict criteria. However, in a nonscreening clinical situa-
tion as described herein, such a rigorous study is not prac-
tical inasmuch as the decision to perform a biopsy of an
IPN is based not only on nodule growth, but also otherery c August 2011
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factors, PET findings, and nodule appearance), as de-
scribed above.
A third limitation is that the automated volumetric anal-
ysis does not reliably segment ground glass opacities, and
these were therefore excluded from this study. The differ-
ence in density and contrast and lack of discrete boundaries
between pure ground glass nodules and normal pulmonary
parenchyma is insufficient for the software to reliably dis-
criminate between them. With further technological ad-
vances in software programs and hardware, the ability to
reliably segment ground glass opacities from background
pulmonary parenchyma will likely increase.
A final limitation of the present study is that the histo-
logic diagnosis of all 87 nodules was not obtained, so the
true rate of false-negatives and false-positives associated
with volumetric growth analysis is not known. Given that
the majority of IPN are benign, it is difficult to justify his-
tologic confirmation in all cases.
In summary, this study is unique because it describes the
correlation between pulmonary nodule growth rates obtained
by automated volumetric software and conventional, 2D
measurements, as well as the impact of the use of volumetric
analysis on clinical decisionmaking.Although the results are
preliminary andworthy of further investigation, the data sug-
gest that 2D growth measurements seem to be highly corre-
lated with those obtained using automated volumetric
software.Circumstanceswherevolumetric analysismaypro-
vide additional information include the evaluation of spicu-
lated/lobulated lesions, as well as when the time interval
between scans is relatively short. Although the addition of
volumetric growth analysis changed biopsy decisions in
only a minority of instances, lung cancer was commonly di-
agnosed in this minority. Radiographic lung cancer growth is
highly variable, with many cancers actually shrinking at
some point, suggesting that the use of nodule growth as the
primary determinate of biopsy should be reconsidered.The Journal of Thoracic and CaReferences
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